Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

NCT04563871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: 80mg Osimertinib

Sponsor

Samsung Medical Center

Collaborators

[object Object]